Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...

Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...

Shy Drager syndrome was the name for the condition now known as multiple system atrophy (MSA), a neurological condition first recognized in the 1960s. It was traditionally diagnosed when someone began ...

Alterity Therapeutics (ATHE) announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy ...

Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...

α-synuclein is a neuronal protein involved in functions like vesicle trafficking and neurotransmitter release. It is typically found in abundance in a healthy brain. However, the aggregation of ...

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. New ...

"Multiple System Atrophy Clinical Trials Analysis"DelveInsight's,“Multiple System Atrophy- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in ...

MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...